Logo image of VLA.PA

VALNEVA SE (VLA.PA) Stock Fundamental Analysis

EPA:VLA - Euronext Paris - Matif - FR0004056851 - Common Stock - Currency: EUR

2.854  -0.01 (-0.49%)

Fundamental Rating

3

VLA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. Both the profitability and financial health of VLA have multiple concerns. VLA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year VLA has reported negative net income.
In the past year VLA has reported a negative cash flow from operations.
In the past 5 years VLA always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: VLA reported negative operating cash flow in multiple years.
VLA.PA Yearly Net Income VS EBIT VS OCF VS FCFVLA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

VLA has a better Return On Assets (7.48%) than 86.30% of its industry peers.
VLA has a Return On Equity of 20.65%. This is amongst the best in the industry. VLA outperforms 89.04% of its industry peers.
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
VLA.PA Yearly ROA, ROE, ROICVLA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

With an excellent Profit Margin value of 15.08%, VLA belongs to the best of the industry, outperforming 84.93% of the companies in the same industry.
VLA has a Gross Margin (41.01%) which is comparable to the rest of the industry.
VLA's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 15.08%
GM 41.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
VLA.PA Yearly Profit, Operating, Gross MarginsVLA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VLA has more shares outstanding
VLA has more shares outstanding than it did 5 years ago.
VLA has a better debt/assets ratio than last year.
VLA.PA Yearly Shares OutstandingVLA.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
VLA.PA Yearly Total Debt VS Total AssetsVLA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -0.11, we must say that VLA is in the distress zone and has some risk of bankruptcy.
VLA has a Altman-Z score of -0.11. This is comparable to the rest of the industry: VLA outperforms 49.32% of its industry peers.
VLA has a Debt/Equity ratio of 1.06. This is a high value indicating a heavy dependency on external financing.
VLA has a Debt to Equity ratio (1.06) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Altman-Z -0.11
ROIC/WACCN/A
WACC8.84%
VLA.PA Yearly LT Debt VS Equity VS FCFVLA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

VLA has a Current Ratio of 2.61. This indicates that VLA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.61, VLA is in line with its industry, outperforming 56.16% of the companies in the same industry.
VLA has a Quick Ratio of 2.14. This indicates that VLA is financially healthy and has no problem in meeting its short term obligations.
VLA has a Quick ratio (2.14) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 2.14
VLA.PA Yearly Current Assets VS Current LiabilitesVLA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

VLA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -184.21%.
Looking at the last year, VLA shows a quite strong growth in Revenue. The Revenue has grown by 10.32% in the last year.
Measured over the past years, VLA shows a small growth in Revenue. The Revenue has been growing by 6.09% on average per year.
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%

3.2 Future

VLA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 119.91% yearly.
The Revenue is expected to grow by 24.84% on average over the next years. This is a very strong growth
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue Next Year6.9%
Revenue Next 2Y17.55%
Revenue Next 3Y26.72%
Revenue Next 5Y24.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VLA.PA Yearly Revenue VS EstimatesVLA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
VLA.PA Yearly EPS VS EstimatesVLA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VLA.PA Price Earnings VS Forward Price EarningsVLA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VLA.PA Per share dataVLA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as VLA's earnings are expected to grow with 119.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-69.87%
EPS Next 3Y119.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE

EPA:VLA (5/27/2025, 5:28:43 PM)

2.854

-0.01 (-0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners29.31%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap238.52M
Analysts83.33
Price Target7.43 (160.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31.52%
Min EPS beat(2)-115.24%
Max EPS beat(2)52.2%
EPS beat(4)2
Avg EPS beat(4)-8.58%
Min EPS beat(4)-115.24%
Max EPS beat(4)72.74%
EPS beat(8)4
Avg EPS beat(8)-10.16%
EPS beat(12)5
Avg EPS beat(12)-55.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.78%
Max Revenue beat(2)1.77%
Revenue beat(4)1
Avg Revenue beat(4)-7.74%
Min Revenue beat(4)-14.39%
Max Revenue beat(4)1.77%
Revenue beat(8)4
Avg Revenue beat(8)-2.47%
Revenue beat(12)6
Avg Revenue beat(12)43.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.45%
PT rev (3m)-4.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45.45%
EPS NY rev (1m)0%
EPS NY rev (3m)1.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.88%
Revenue NY rev (1m)0.64%
Revenue NY rev (3m)-4.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.96
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.53
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS2.97
BVpS2.17
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 15.08%
GM 41.01%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.96%
Cap/Sales 6.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 2.14
Altman-Z -0.11
F-Score5
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%
Revenue Next Year6.9%
Revenue Next 2Y17.55%
Revenue Next 3Y26.72%
Revenue Next 5Y24.84%
EBIT growth 1Y82.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-262.99%
EBIT Next 3Y35.74%
EBIT Next 5Y30.38%
FCF growth 1Y61.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.85%
OCF growth 3YN/A
OCF growth 5YN/A